Plain-English translation of NCT06066645 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a combination approach for treating glaucoma and high eye pressure. You would receive either a small implant in your eye called iStent infinite plus a (a medication-releasing device), or a sham procedure plus the medication implant alone. Researchers want to see if combining these two treatments works better and is safe over a 12-month period.
Glaucoma and high eye pressure can damage vision and lead to blindness if not controlled well with current treatments. This trial explores whether combining a tiny implant that improves fluid drainage in the eye with a medication implant that slowly releases medicine could work better than the medication implant alone.
You likely qualify if…
You likely don't qualify if…
You will have eye surgery where doctors will place an implant in your eye. Half of participants will receive both the iStent infinite implant and the medication implant; the other half will receive a sham procedure plus the medication implant. After your procedure, you'll visit the clinic for check-ups over 12 months so doctors can monitor your eye pressure, vision, and how well the treatment is working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
Glaukos Corporation
Enrollment target
~150 participants
Started
September 2023
Primary completion
May 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Study Director
Glaukos Corporation
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.